Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: Press release

Transgene successfully raises € 14.4 million from U.S. and European investors

PR success ABB Transgene

Published 10 November 2017
Categorized as 2017, Press release

Transgene launches a capital increase by way of an accelerated book build offering

20171109 Transgene_Private placement

Published 9 November 2017
Categorized as Press release

Transgene to Present Additional Immunology Data from the TIME trial with TG4010 in patients with advanced lung cancer at SITC 2017

20171030 PR SITC TG4010

Published 30 October 2017
Categorized as 2017, Press release

First Patient Treated in a Phase 1/2a Trial (Oncovirac) of Novel Oncolytic Virus TG6002 in Recurrent Glioblastoma

20171026-PR-TG6002

Published 26 October 2017
Categorized as 2017, Press release, TG6002

TG1050 is well tolerated and induces a strong specific immune response in patients with chronic hepatitis B

20171023 PR post AASLD TG1050 final. docx

Published 23 October 2017
Categorized as 2017, Press release, TG1050

Third Quarter Marked by Progress in Clinical Development and Research

171019 PR Q3-2017 FINAL

Published 19 October 2017
Categorized as 2017, Press release

Transgene Presents First Clinical Data Indicating that TG1050 Induces a Robust and HBV-Specific Cell-Mediated Immune Response in Patients with Chronic Hepatitis B

20171017 PR AASLD TG1050 final

Published 17 October 2017
Categorized as 2017, Press release, TG1050

Peer Reviewed Scientific Publications Highlight TG4010’s Ability to Induce Broad CD8+ Responses and its Synergistic Effects in Combination with Immune Checkpoint Inhibitors

20171012 PR TG4010 publications

Published 12 October 2017
Categorized as 2017, Press release, TG4010

Transgene and Randox Sign Collaboration to Develop Innovative Multifunctional Oncolytic Virotherapies for Solid Tumors

20171002-PR-TG-Randox-final

Published 2 October 2017
Categorized as 2017, Invir.IO, Press release

Transgene Launches Invir.IO™, its Integrated Platform for the Next Generation of Multifunctional Oncolytic Viruses

20170905 Invirio PR US

Published 21 September 2017
Categorized as 2017, Invir.IO, Press release

Posts pagination

Newer posts Page 1 … Page 26 … Page 33 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu